A. Othman

发表

Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease Patients

D. Nyholm, A. Johansson, S. Dutta, 2013, The AAPS Journal.

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study

K. Kieburtz, D. Standaert, Hubert H. Fernandez, 2014, The Lancet Neurology.

Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety

S. Dutta, K. Chatamra, A. Othman, 2015, Clinical Pharmacokinetics.

Metabolism and Disposition of a Novel Selective α7 Neuronal Acetylcholine Receptor Agonist ABT-126 in Humans: Characterization of the Major Roles for Flavin-Containing Monooxygenases and UDP-Glucuronosyl Transferase 1A4 and 2B10 in Catalysis

J. Sydor, Xiaofen Li, Hong Liu, 2018, Drug Metabolism and Disposition.

Exposure–Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection

A. Othman, M. Mohamed, B. Klünder, 2019, Clinical pharmacology and therapeutics.

Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis

A. Camez, A. Othman, Yinuo Pang, 2018, Clinical Pharmacokinetics.

Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus Erythematosus

A. Nader, A. Othman, M. Minocha, 2019, Clinical Pharmacokinetics.

A Phase 1 Study to Evaluate the Bioavailability and Food Effect of 2 Solid‐Dispersion Formulations of the TRPV1 Antagonist ABT‐102, Relative to the Oral Solution Formulation, in Healthy Human Volunteers

S. Dutta, C. Locke, A. Othman, 2012, Clinical pharmacology in drug development.

Fibroblast growth factor-6 enhances and expression in microvesicles derived from CDK 2 MAKT human stem cells extracted from exfoliated deciduous teeth

Sabry, A. Othman, 2020 .

Fibroblast growth factor-6 enhances CDK2 and MATK expression in microvesicles derived from human stem cells extracted from exfoliated deciduous teeth.

D. Sabry, A. Othman, R. Mubarak, 2020, F1000Research.

Fibroblast growth factor-6 enhances CDK2 and MATK expression in microvesicles derived from human stem cells extracted from exfoliated deciduous teeth.

D. Sabry, A. Othman, R. Mubarak, 2020, F1000Research.

Fibroblast growth factor-6 enhances CDK2 and MAKT expression in microvesicles derived from human stem cells extracted from exfoliated deciduous teeth.

D. Sabry, A. Othman, R. Mubarak, 2018, F1000Research.

Fibroblast growth factor-6 enhances CDK2 and MATK expression in microvesicles derived from human stem cells extracted from exfoliated deciduous teeth

D. Sabry, A. Othman, R. Mubarak, 2020, F1000Research.

Fibroblast growth factor-6 enhances CDK2 and MATK expression in microvesicles derived from human stem cells extracted from exfoliated deciduous teeth.

D. Sabry, A. Othman, R. Mubarak, 2019, F1000Research.

Fibroblast growth factor-6 enhances CDK2 and MAKT expression in microvesicles derived from human stem cells extracted from exfoliated deciduous teeth.

D. Sabry, A. Othman, R. Mubarak, 2018, F1000Research.

Exposure‐Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis—Analyses of Phase 2b Study to Support Selection of Phase 3 Doses

S. Gopalakrishnan, A. Othman, M. Mohamed, 2020, Journal of clinical pharmacology.

Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial.

J. Silverberg, K. Papp, K. Reich, 2019, Journal of Allergy and Clinical Immunology.

Single‐ and Multiple‐Dose Pharmacokinetics, Safety, and Tolerability of the Selective α7 Neuronal Nicotinic Receptor Agonist, ABT‐107, in Healthy Human Volunteers

S. Dutta, Jun Zhang, A. Othman, 2011, Journal of clinical pharmacology.

Meta‐Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority

P. Diderichsen, J. Mandema, A. Othman, 2019, Clinical pharmacology and therapeutics.

Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis

J. Elkins, Alvydas Mikulskis, A. Othman, 2016, Clinical pharmacology : advances and applications.

Evaluation of the potential for pharmacokinetic interaction between tirabrutinib and levonorgestrel/ethinyl estradiol in healthy female volunteers

C. Nelson, A. Othman, G. Cherala, 2022, Clinical and translational science.

Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics

T. Marbury, A. Othman, M. Mohamed, 2019, Journal of clinical pharmacology.

Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials

A. Othman, M. Mohamed, B. Klünder, 2019, Clinical Pharmacokinetics.

Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high‐fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib

P. Jiang, A. Othman, M. Mohamed, 2017, British journal of clinical pharmacology.

Length Safety , Tolerability , and Pharmacodynamics of ABT-122 , a TNF-and IL-17 – Targeted Dual Variable Domain Immunoglobulin , in Patients With RA Running Title : ABT-122 safety and pharmacodynamics

M. Ruzek, P. Jiang, R. Fleischmann, 2017 .

Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis

P. Jiang, A. Othman, M. Mohamed, 2016, Clinical Pharmacokinetics.

Population PK-PD analyses of CD25 occupancy, CD56bright NK cell expansion, and regulatory T cell reduction by daclizumab HYP in subjects with multiple sclerosis.

I. Nestorov, A. Othman, Yaming Hang, 2016, British journal of clinical pharmacology.

Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis

P. Peloso, M. Genovese, M. Weinblatt, 2018, Rheumatology.

Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa

S. Dutta, K. Chatamra, C. Locke, 2017, Journal of Parkinson's disease.

Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants

C. Nelson, A. Othman, Kacey B. Anderson, 2021, Clinical pharmacology in drug development.

Development of In Vitro–In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation

P. Marroum, A. Othman, M. Mohamed, 2019, The AAPS Journal.

Population Pharmacokinetics of the TNF‐α and IL‐17A Dual‐Variable Domain Antibody ABT‐122 in Healthy Volunteers and Subjects With Psoriatic or Rheumatoid Arthritis: Analysis of Phase 1 and 2 Clinical Trials

A. Othman, A. Khatri, Amit Khatri, 2018, Journal of clinical pharmacology.

Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials

P. Jiang, A. Othman, H. Mansikka, 2018, Clinical Pharmacokinetics.

Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials

A. Othman, M. Minocha, A. Suleiman, 2018, Clinical Pharmacokinetics.

Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects

A. Othman, M. Mohamed, H. Camp, 2021, Clinical pharmacology in drug development.

Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients

A. Othman, A. Suleiman, Yinuo Pang, 2019, Clinical Pharmacokinetics.

Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis

A. Othman, A. Suleiman, R. Oberoi, 2019, Journal of clinical pharmacology.

Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials

A. Othman, M. Minocha, A. Suleiman, 2019, Clinical Pharmacokinetics.

Exposure–Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis

A. Othman, A. Suleiman, R. Oberoi, 2019, Clinical Pharmacokinetics.

Pharmacokinetics, Safety, and Tolerability of the Dual Inhibitor of Tumor Necrosis Factor‐α and Interleukin 17A, ABBV‐257, in Healthy Volunteers and Patients With Rheumatoid Arthritis

P. Peloso, R. Loebbert, A. Othman, 2018, Clinical pharmacology in drug development.

Therapeutic Protein Drug Interaction Potential in Subjects With Psoriasis: An Assessment Based on Population Pharmacokinetic Analyses of Sensitive Cytochrome P450 Probe Substrates

A. Othman, M. Mohamed, A. Sathe, 2020, Journal of clinical pharmacology.

Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials

A. Nader, A. Othman, M. Mohamed, 2019, Journal of clinical pharmacology.

Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.

P. Higgins, G. D'Haens, W. Sandborn, 2020, Gastroenterology.

Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.

J. Lewis, G. D'Haens, G. Van Assche, 2020, Gastroenterology.

Exposure–Response Analyses for Upadacitinib Efficacy and Safety in the Crohn's Disease CELEST Study and Bridging to the Extended‐Release Formulation

A. Othman, M. Mohamed, B. Klünder, 2019, Clinical pharmacology and therapeutics.

Molecular characterization of vitellogenesis in anautogenous Culex pipiens pipiens L. mosquitoes.

M. Shehata, A. Othman, Y. M. A. El-Latif, 2017 .

Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers.

S. Dutta, Jun Zhang, C. Locke, 2013, British journal of clinical pharmacology.

Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials

A. Othman, M. Mohamed, B. Klünder, 2017, Clinical Pharmacokinetics.

Models of Variability and Circadian Rhythm in Heart Rate, Blood Pressure, and QT Interval for Healthy Subjects Who Received Placebo in Phase I Trials

Y. Chiu, A. Othman, M. Minocha, 2019, Clinical and translational science.

Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials

J. Sheridan, A. Othman, M. Minocha, 2015, Clinical Pharmacokinetics.

Double-Blind, Double-Dummy, Randomized Study of Continuous Intrajejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease

K. Kieburtz, D. Standaert, Hubert H. Fernandez, 2022 .

The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects

A. Othman, M. Mohamed, A. Friedman, 2018, Journal of clinical pharmacology.

Title : Metabolism and Disposition of a Novel Selective 7 Neuronal Acetylcholine Receptor Agonist ABT-126 in Humans : Characterization of the Major Roles for Flavin-containing Monooxygenases and UDP-glucuronosyl Transferase 1 A 4 and 2 B 10 in Catalysis

J. Sydor, Xiaofen Li, Hong Liu, 2018 .

A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.

A. Othman, W. Robieson, E. Bain, 2016, The American journal of psychiatry.

Exposure–response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritis

P. Peloso, A. Othman, B. Klünder, 2018, Rheumatology.

Phase II Study of ABT‐122, a Tumor Necrosis Factor– and Interleukin‐17A–Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate

P. Peloso, M. Genovese, M. Weinblatt, 2018, Arthritis & rheumatology.

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.

A. Kaser, O. Dewit, D. Franchimont, 2018, The lancet. Gastroenterology & hepatology.

Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I–III Clinical Trials

I. Nestorov, A. Othman, Yaming Hang, 2016, Clinical Pharmacokinetics.

Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus

A. Othman, M. Minocha, J. Medema, 2018, Clinical Pharmacokinetics.

Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia

C. Chuang-Stein, L. Shafner, A. Othman, 2017, JMIR mHealth and uHealth.

Phase 1 first-in-human study of dalutrafusp alfa, an anti–CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors

A. Tolcher, J. Strauss, A. Othman, 2023, Journal for ImmunoTherapy of Cancer.

ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension

C. Ritchie, S. Berry, A. Othman, 2016, Alzheimer's Research & Therapy.

Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers: Integrated Analysis of Intravenous and Subcutaneous, Single- and Multiple-Dose Administration

S. Dutta, A. Othman, M. Tang, 2014, Clinical Pharmacokinetics.

Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study

M. Kawano, Yoshiya Tanaka, T. Takeuchi, 2020, Rheumatology.

Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial

C. Peterfy, M. Genovese, P. Durez, 2019, Arthritis & rheumatology.

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study

P. Emery, Yoshiya Tanaka, J. Smolen, 2019, The Lancet.

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

J. Kremer, G. Burmester, A. Kivitz, 2018, The Lancet.

Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

M. Genovese, M. Weinblatt, G. Burmester, 2016, Arthritis & Rheumatology.

A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy

J. Kremer, P. Emery, E. Keystone, 2016, Arthritis & rheumatology.

Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail

J. Enejosa, A. Othman, M. Mohamed, 2019, Journal of clinical pharmacology.

Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics

T. Marbury, A. Othman, M. Mohamed, 2019, Journal of clinical pharmacology.

Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended‐Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials

P. Marroum, A. Othman, M. Mohamed, 2018, Clinical pharmacology in drug development.

Use of Early Clinical Trial Data to Support Thorough QT Study Waiver for Upadacitinib and Utility of Food Effect to Demonstrate ECG Assay Sensitivity

B. Hosmane, P. Jiang, A. Othman, 2017, Clinical pharmacology and therapeutics.

Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease Patients

D. Nyholm, A. Johansson, S. Dutta, 2013, The AAPS Journal.

Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets

S. Dutta, A. Othman, 2014, British journal of clinical pharmacology.

Therapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach.

J. Elkins, A. Othman, J. Q. Tran, 2016, British journal of clinical pharmacology.

The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study

A. Othman, G. Haig, Jun Zhao, 2016, Neuropsychopharmacology.

A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia.

A. Othman, W. Robieson, R. Lenz, 2014, Schizophrenia bulletin.

A phase 2 randomized, controlled trial of the α7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia

C. Ritchie, A. Othman, W. Robieson, 2015, Alzheimer's & dementia.

Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.

S. Gauthier, Yunzhi Lin, A. Othman, 2016, Journal of Alzheimer's disease : JAD.

A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia.

A. Othman, Y. Pritchett, R. Lenz, 2014, Journal of Alzheimer's disease : JAD.

Development and validation of a stability-indicating RP-LC method for the simultaneous determination of otilonium bromide and its expected degradation product in bulk drug and pharmaceutical preparation

A. Othman, E. Elkady, R. El-Bagary, 2016 .

The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers.

S. Dutta, C. Locke, A. Othman, 2014, British journal of clinical pharmacology.

OP0036 A phase 3 randomised, placebo-controlled, double-blind study of upadacitinib (ABT-494), a selective jak-1 inhibitor, in patients with active rheumatoid arthritis with inadequate response to conventional synthetic dmards

J. Kremer, G. Burmester, F. E. Van den Bosch, 2018, WEDNESDAY, 13 JUNE 2018.

Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Alicapistat, a Selective Inhibitor of Human Calpains 1 and 2 for the Treatment of Alzheimer Disease: An Overview of Phase 1 Studies

C. Locke, A. Othman, N. Mendonça, 2018, Clinical pharmacology in drug development.

Exposure–Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit–Risk Assessment in Rheumatoid Arthritis

A. Nader, A. Othman, M. Mohamed, 2019, Clinical pharmacology and therapeutics.

Utility of Modeling and Simulation Approach to Support the Clinical Relevance of Dissolution Specifications: a Case Study from Upadacitinib Development

P. Marroum, A. Othman, M. Mohamed, 2022, The AAPS Journal.

Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate

J. Enejosa, A. Othman, M. Mohamed, 2020, Clinical pharmacology in drug development.

Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure‐Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib

A. Othman, M. Mohamed, H. Camp, 2019, Journal of clinical pharmacology.

Effects of the TRPV1 antagonist ABT-102 on body temperature in healthy volunteers: pharmacokinetic/ pharmacodynamic analysis of three phase 1 trials.

S. Dutta, A. Othman, W. Awni, 2013, British journal of clinical pharmacology.

Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication

A. Othman, M. Mohamed, B. Klünder, 2019, Clinical Pharmacokinetics.

ABT‐122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin‐17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate

P. Peloso, M. Genovese, M. Weinblatt, 2018, Arthritis & rheumatology.

An oral TRPV1 antagonist attenuates laser radiant‐heat‐evoked potentials and pain ratings from UVB‐inflamed and normal skin

P. Reeh, C. Locke, A. Othman, 2013, British journal of clinical pharmacology.

Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers.

A. Othman, E. Bain, G. Haig, 2017, The Journal of clinical psychiatry.

060 Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate

P. Emery, J. Smolen, A. Othman, 2019, Rheumatology.

AB0478 Mild and moderate hepatic impairment have no clinically relevant impact on upadacitinib pharmacokinetics: results from a dedicated phase 1 study

A. Othman, A. Lacerda, T. Feng, 2018, Rheumatoid arthritis – non biologic treatment and small molecules.

AB0390 Safety and Efficacy of ABT-494, A Novel Selective JAK1 Inhibitor, in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance To Anti-TNF Biologic Therapy

P. Emery, E. Keystone, A. Othman, 2016 .

Safety, Tolerability, and Pharmacodynamics of ABT‐122, a Tumor Necrosis Factor– and Interleukin‐17–Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis

M. Ruzek, P. Jiang, R. Fleischmann, 2017, Arthritis & rheumatology.

Phase 2 Study of ABT-122, a TNF- and IL-17A-Targeted Dual Variable Domain Immunoglobulin, in Psoriatic Arthritis With Inadequate Methotrexate Response.

P. Peloso, M. Genovese, M. Weinblatt, 2018 .

Exposure–Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients

A. Othman, A. Suleiman, Akshanth R. Polepally, 2019, Clinical pharmacology and therapeutics.

EFFICACY AND SAFETY OF THE ALPHA7 AGONIST ABT-126 AS A MONOTHERAPY TREATMENT IN MILD-TO-MODERATE ALZHEIMER'S DEMENTIA: RESULTS OF A PHASE 2B TRIAL

C. Ritchie, A. Othman, L. Gault, 2014, Alzheimer's & Dementia.

The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers.

S. Dutta, C. Locke, A. Othman, 2014, British journal of clinical pharmacology.

Therapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach.

J. Elkins, A. Othman, J. Q. Tran, 2016, British journal of clinical pharmacology.